Telavancin in the treatment of invasive Gram-positive infections

vancin in the treatment of invasive Gram-positive infections Review (625) Total Article Views Authors: Keynan Y, Rubinstein E Published Date November 2012 Volume 2012:4 Pages 25 - 29 DOI: http://dx.doi.org/10.2147/CA.S30127 Received: 05 March 2012 Accepted: 11 August 2012 Published: 01 November 2012 Yoav Keynan,1–4 Ethan Rubinstein2,3 1Department of Community Health Sciences, 2Department of Medical Microbiology, 3Department of Internal Medicine, University of Manitoba, Winnipeg, Canada; 4Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya Abstract: Telavancin is a newer once-daily lipoglycopeptide with activity against Gram-positive bacteria, including those that are resistant to conventional antibiotics like beta-lactams. The results of recent clinical trials led to registration of telavancin for use in skin and skin structure infections in the US and Canada and for nosocomial pneumonia in Europe, based primarily on the favorable results of clinical trials. We review the evidence for use of telavancin in Gram-positive intravascular infections, focusing on bacteremic subpopulations in the large clinical trials as well as anecdotal evidence for use of the drug in the setting of infective endocarditis.